Aaron Royston

Managing Partner

2015 - Current

venBio is a life science venture capital firm that focuses on novel therapeutics for unmet medical needs. Since inception in 2011, venBio has raised nearly $1.5 billion in capital commitments and led investment rounds in 35+ companies, including: Labrys Biologics (acquired by Teva); ALX Oncology (NASDAQ: ALXO); Aragon Pharmaceuticals (acquired by Johnson & Johnson); Seragon Pharmaceuticals (acquired by Roche); Aurinia Pharmaceuticals (NASDAQ: AUPH); Apellis Pharmaceuticals (NASDAQ: APLS); Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS); Precision Biosciences (NASDAQ: DTIL); Akero Therapeutics (NASDAQ: AKRO); Harmony Biosciences (NASDAQ: HRMY); Pharvaris (NASDAQ: PHVS); Ventyx Biosciences (NASDAQ: VTYX); CinCor Pharma (NASDAQ: CINC, acquired by AstraZeneca), and RayzeBio (NASDAQ: RYZB, acquired by BMS).

Board of Directors

2023

Board of Directors

2022

Board of Directors

2021

Board of Directors

2021

Board Of Directors

2017

Board of Directors

2020 - 2023

IPO in September 2023 (NASDAQ: RYZB) Acquired by Bristol Myers Squibb in December 2023 for $4.1B

Board of Directors

2021 - 2023

IPO in October 2021 (NASDAQ: VTYX)

Board Of Directors

2017 - 2020

IPO in August 2020 (NASDAQ: HRMY) FDA approvals for Wakix in Aug 2019, Oct 2020, and Jun 2024.

Board Of Directors

2018 - 2019

IPO in June 2019 (NASDAQ: AKRO)